Comparison of weekly docetaxel regimens in prostate cancer: a systematic review and frequentist network meta-analysis.
메타분석
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
238 patients were included.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Triweekly dosing prolongs time to treatment failure but is associated with greater toxicity, whereas weekly dosing offers better tolerability. Treatment decisions should balance efficacy and safety based on individual patient characteristics.
[BACKGROUND] Docetaxel is a cornerstone chemotherapy for metastatic hormone-sensitive and castration-resistant prostate cancer.
- 95% CI 0.52-1.22
- RR 0.79
- 연구 설계 meta-analysis
APA
Rath S, Sajjad F, et al. (2026). Comparison of weekly docetaxel regimens in prostate cancer: a systematic review and frequentist network meta-analysis.. Exploration of targeted anti-tumor therapy, 7, 1002360. https://doi.org/10.37349/etat.2026.1002360
MLA
Rath S, et al.. "Comparison of weekly docetaxel regimens in prostate cancer: a systematic review and frequentist network meta-analysis.." Exploration of targeted anti-tumor therapy, vol. 7, 2026, pp. 1002360.
PMID
41773084 ↗
Abstract 한글 요약
[BACKGROUND] Docetaxel is a cornerstone chemotherapy for metastatic hormone-sensitive and castration-resistant prostate cancer. Although the standard triweekly regimen is widely used, weekly and biweekly schedules are often employed to improve tolerability, particularly in elderly or frail patients. The comparative efficacy and safety of these dosing strategies remain unclear. This study aimed to systematically compare weekly, biweekly, and triweekly docetaxel regimens using a network meta-analysis.
[METHODS] MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials were searched from inception to February 2025. Randomized controlled trials and observational retrospective studies comparing weekly, biweekly, and triweekly docetaxel regimens were included. Outcomes assessed were prostate-specific antigen (PSA) response rate, time to treatment failure or progression, and adverse events. A frequentist random-effects network meta-analysis was conducted using R software.
[RESULTS] Eleven studies involving 1,238 patients were included. PSA response rates did not differ significantly among regimens; triweekly docetaxel showed a numerically lower response compared with weekly dosing (RR = 0.79, 95% CI 0.52-1.22; = 41.1%). Time to treatment failure was significantly longer with triweekly dosing compared with weekly dosing (mean difference = 10.91 months, 95% CI 6.94-14.87; = 96.8%). Biweekly and triweekly regimens were associated with significantly higher hepatotoxicity compared with weekly dosing (RR = 3.71 and RR = 3.21, respectively; = 0%). Vomiting was more frequent with triweekly docetaxel (RR = 2.47, 95% CI 1.31-4.63). No significant differences were observed for overall adverse events, hematologic toxicity, neuropathy, fatigue, febrile neutropenia, nausea, anorexia, or diarrhea.
[DISCUSSION] Docetaxel dosing schedules show comparable PSA response rates. Triweekly dosing prolongs time to treatment failure but is associated with greater toxicity, whereas weekly dosing offers better tolerability. Treatment decisions should balance efficacy and safety based on individual patient characteristics.
[METHODS] MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials were searched from inception to February 2025. Randomized controlled trials and observational retrospective studies comparing weekly, biweekly, and triweekly docetaxel regimens were included. Outcomes assessed were prostate-specific antigen (PSA) response rate, time to treatment failure or progression, and adverse events. A frequentist random-effects network meta-analysis was conducted using R software.
[RESULTS] Eleven studies involving 1,238 patients were included. PSA response rates did not differ significantly among regimens; triweekly docetaxel showed a numerically lower response compared with weekly dosing (RR = 0.79, 95% CI 0.52-1.22; = 41.1%). Time to treatment failure was significantly longer with triweekly dosing compared with weekly dosing (mean difference = 10.91 months, 95% CI 6.94-14.87; = 96.8%). Biweekly and triweekly regimens were associated with significantly higher hepatotoxicity compared with weekly dosing (RR = 3.71 and RR = 3.21, respectively; = 0%). Vomiting was more frequent with triweekly docetaxel (RR = 2.47, 95% CI 1.31-4.63). No significant differences were observed for overall adverse events, hematologic toxicity, neuropathy, fatigue, febrile neutropenia, nausea, anorexia, or diarrhea.
[DISCUSSION] Docetaxel dosing schedules show comparable PSA response rates. Triweekly dosing prolongs time to treatment failure but is associated with greater toxicity, whereas weekly dosing offers better tolerability. Treatment decisions should balance efficacy and safety based on individual patient characteristics.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (2)
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Real-world Treatment Selection and Shared Decision-making in De Novo Metastatic Castration-sensitive Prostate Cancer in Japan.
- Comparative efficacy of combination regimens based on interventional therapy and immune checkpoint inhibitors (ICIs) in patients with intermediate- and advanced-stage hepatocellular carcinoma: a systematic review, meta-analysis, and network meta-analysis.
- Pharmacokinetics and Customized Dosing of Vancomycin in Adult Patients With Hematological Malignancies: Status, Challenges, and Opportunities.
- Randomized Comparison of Cardiotoxicity With 60 Versus 90 mg Daunorubicin in AML Induction Therapy.
- Re-evaluating Treatments for Advanced Urothelial Carcinoma Using Restricted Mean Survival Time: A Systematic Review and Network Meta-analysis.
- Efficacy and tolerability of first-line treatment regimens for extensive-stage small cell lung cancer - a grade-assessed network meta-analysis of randomized controlled trials.